Alerts will be sent to your verified email
Verify EmailNGLFINE
NGL Fine-Chem
|
Hikal
|
Sequent Scientific
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Total reactor capacity
|
457.0 kL | 145.0 kL | n/a |
R&D as a % of Total Sales
|
1.8 % | 4.01 % | 0.0 |
Financials
|
|||
5 yr Average ROE
|
18.68 % | 10.48 % | -0.13 % |
5yr average Equity Multiplier
|
1.37 | 2.17 | 2.16 |
5yr Average Asset Turnover Ratio
|
1.03 | 0.81 | 0.95 |
5yr Avg Net Profit Margin
|
12.56 % | 5.87 % | 0.03 % |
Price to Book
|
2.88 | 3.1 | 5.98 |
P/E
|
39.0 | 43.07 | 192.63 |
5yr Avg Cash Conversion Cycle
|
24.74 Days | 33.87 Days | 49.09 Days |
Inventory Days
|
47.94 Days | 64.21 Days | 80.25 Days |
Days Receivable
|
84.83 Days | 101.46 Days | 79.76 Days |
Days Payable
|
83.75 Days | 96.57 Days | 114.46 Days |
5yr Average Interest Coverage Ratio
|
25.7 | 4.8 | 1.93 |
5yr Avg ROCE
|
24.83 % | 13.73 % | 6.67 % |
5yr Avg Operating Profit Margin
|
18.08 % | 16.42 % | 7.74 % |
5 yr average Debt to Equity
|
0.16 | 0.68 | 0.53 |
5yr CAGR Net Profit
|
-18.08 % | -3.79 % | -25.52 % |
5yr Average Return on Assets
|
13.76 % | 4.82 % | 0.05 % |
Shareholdings
|
|||
Promoter Holding
|
72.74 % | 68.85 % | 52.61 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-1.07 % | 0.08 % | -0.18 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 2.2 % | 9.79 % |
NGL Fine-Chem
|
Hikal
|
Sequent Scientific
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|